|
Video: What is a Stock Split?
|
|
Catalyst Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. Co.'s main US commercial product is FIRDAPSE® (amifampridine) Tablets 10 mg approved for the treatment of Lambert-Eaton myasthenic syndrome for adults and for children ages six and up. Co. has the US rights to FYCOMPA®(perampanel) CIII, a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat generalized tonic-clonic seizures in people with epilepsy aged 12 and older. According to our Catalyst Pharmaceuticals stock split history records, Catalyst Pharmaceuticals has had 0 splits. | |
|
Catalyst Pharmaceuticals (CPRX) has 0 splits in our Catalyst Pharmaceuticals stock split history database.
Looking at the Catalyst Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Catalyst Pharmaceuticals shares, starting with a $10,000 purchase of CPRX, presented on a split-history-adjusted basis factoring in the complete Catalyst Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$2.32 |
|
End price/share: |
$15.94 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
587.07% |
|
Average Annual Total Return: |
21.26% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$68,698.35 |
|
Years: |
10.00 |
|
|
|
|
|